Features include: Abnormal vestibulocochlear nerve morphology, Vertigo, Cochlear degeneration, and Postlingual sensorineural hearing impairment and 1 more.

COCH encodes cochlin (550 aa). Plays a role in the control of cell shape and motility in the trabecular meshwork Highest expression in Brain Nucleus accumbens basal ganglia (51.8 TPM) and Brain Caudate basal ganglia (37.3 TPM).

Autosomal dominant nonsyndromic hearing loss 9 is associated with mutations in the COCH gene on chromosome 14.

The COCH protein participates in Unknown NAT transfers COCH3 to AFXBO-C, AFNBO-C, Mechanoelectrical transduction (MET) channel transports cations into the cytosol of stereocilia of cochlear outer hair cell, and Sensory processing of sound by outer hair cells of the cochlea pathways.

COCH is classified as a druggable target (Druggable Genome and Transporter categories) with score 1.3.

Genetic testing for COCH is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for autosomal dominant nonsyndromic hearing loss 9 has been reported in the published literature.

No clinical trials have been registered for autosomal dominant nonsyndromic hearing loss 9.

19 publications have been identified in PubMed for autosomal dominant nonsyndromic hearing loss 9. Research spans Case Report / Case Series (24%), Basic Science / Preclinical (24%), and Diagnostic / Biomarker (18%).